pdufa.bio
CalendarReadoutsDevicesDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › Readouts › September 2026

September 2026 clinical-trial readouts

trial-readout estimates for September 2026, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.
← August 2026October 2026 →
47 readouts
AVIR · Sep 2026 (est.)
Bemnifosbuvir-Ruzasvir — HEPATITIS C VIRUS CHRONIC INFECTION
ARVN · Sep 2026 (est.)
ARV-471 — Breast Cancer
ARQT · Sep 2026 (est.)
Topical Roflumilast — Hidradenitis Suppurativa
ARDX · Sep 2026 (est.)
Tenapanor — Irritable Bowel Syndrome With Constipation (IBS-C)
GKOS · Sep 2026 (est.)
GLK-321 — Demodex Blepharitis
GILD · Sep 2026 (est.)
Sacituzumab Govitecan — Non-small Cell Lung Cancer
EXEL · Sep 2026 (est.)
Cabozantinib — RCC
DSGN · Sep 2026 (est.)
DT-168 — Fuchs Endothelial Corneal Dystrophy
CORT · Sep 2026 (est.)
Relacorilant — Nonalcoholic Steatohepatitis (NASH)
CGEM · Sep 2026 (est.)
CLN-081 — Multiple Myeloma
BHVN · Sep 2026 (est.)
Taldefgrobep Alfa — Obesity
LEGN · Sep 2026 (est.)
LCAR-B38M CAR-T Cell — Relapsed B-cell Non-Hodgkin Lymphoma
KPTI · Sep 2026 (est.)
Selinexor — Myelofibrosis
IRON · Sep 2026 (est.)
DISC-1459 — Erythropoietic Protoporphyria (EPP)
IOVA · Sep 2026 (est.)
Lifileucel plus Pembrolizumab — Gastric Cancer
APGE · Sep 2026 (est.)
APG777 — Asthma
GPCR · Sep 2026 (est.)
aleniglipron — Obese
VERA · Sep 2026 (est.)
Atacicept — IgA Nephropathy (IgAN)
VNDA · Sep 2026 (est.)
VSJ-110 — Dry Eye
TYRA · Sep 2026 (est.)
TYRA-300 — Locally Advanced Cholangiocarcinoma
SUPN · Sep 2026 (est.)
SPN-812 — Attention-Deficit/Hyperactivity Disorder
SNDX · Sep 2026 (est.)
Revumenib — Idiopathic Pulmonary Fibrosis
SLN · Sep 2026 (est.)
SLN124 — Polycythemia Vera
AGMB · Sep 2026 (est.)
AGMB-129 — Fibrostenotic Crohn's Disease
WVE · Sep 2026 (est.)
WVE-210201 — Alpha-1 Antitrypsin Deficiency
VTVT · Sep 2026 (est.)
Cadisegliatin — Diabetes Mellitus, Type 1
RAPP · Sep 2026 (est.)
RAP-219 — Bipolar 1 Disorder
MAZE · Sep 2026 (est.)
MZE829 — Proteinuric Kidney Disease
PCSA · Sep 2026 (est.)
PCS6422 and capecitabine — Breast Cancer
MRK · Sep 2026 (est.)
Pembrolizumab — Metastatic Triple-Negative Breast Cancer
NVCR · Sep 2026 (est.)
Temozolomide — Anaplastic (Malignant) Meningioma
ORIC · Sep 2026 (est.)
ORIC-114 — Solid Tumors
BMY · Sep 2026 (est.)
Bevacizumab — Advanced Solid Tumors
CORT · Sep 2026 (est.)
Relacorilant — Treatment-resistant PTSD
CRDL · Sep 2026 (est.)
CardiolRx — Recurrent Pericarditis
VIR · Sep 2026 (est.)
VIR-2218 — Hepatic Impairment
BIIB · Sep 2026 (est.)
Litifilimab — Lupus Erythematosus, Systemic
MLTX · Sep 2026 (est.)
Sonelokimab — Hidradenitis Suppurativa
OCGN · Sep 2026 (est.)
OCU410ST — Stargardt Disease
ILMN · Sep 2026 (est.)
18F-MFBG — Parkinson Disease (PD)
IBRX · Sep 2026 (est.)
ALT-803 — Non-muscle Invasive Bladder Cancer
ALEC · Sep 2026 (est.)
AL001 — Alzheimer's Disease
EXEL · Sep 2026 (est.)
Cabozantinib — High Grade Neuroendocrine Neoplasms
CHRS · Sep 2026 (est.)
CHS-1420 — Advanced Solid Tumor
CCCC · Sep 2026 (est.)
Cemsidomide — Multiple Myeloma
BIIB · Sep 2026 (est.)
Litifilimab — Lupus Erythematosus, Systemic
IMMP · Sep 2026 (est.)
eftilagimod alfa — Solid Tumors
Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).